{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:01:14Z","timestamp":1776409274975,"version":"3.51.2"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Electroconvulsive therapy (ECT) has long been used for treating individuals with treatment-resistant depression (TRD). Esketamine has recently emerged as a new treatment for TRD due to its rapid antidepressant effects. To further inform the decision regarding choice of treatment, this paper aims to evaluate whether ECT or esketamine is the more cost-effective option.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The cost-effectiveness was derived as cost per quality-adjusted life-year (QALY) using a Markov model from a societal and life-time perspective. The incremental cost-effectiveness ratio (ICER) was calculated. Health states included different depression and remission states and death. Data to populate the model was derived from randomised controlled trials and other research. Various sensitivity analyses were carried out to test the robustness of the model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The base case scenario shows that ECT is cost-effective compared to esketamine and yields more QALYs at a lower cost. The sensitivity analysis shows that ECT is cost-effective in all scenarios and ECT dominates esketamine in 12 scenarios.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study found that, from a cost-effectiveness point of view, ECT should be the first-hand option for individuals with TRD, when other first line treatments have failed. Considering the lack of economic evaluation of ECT and esketamine, this study is of great value to decision makers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03601-8","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T09:02:52Z","timestamp":1638867772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression"],"prefix":"10.1186","volume":"21","author":[{"given":"Kinza","family":"Degerlund Maldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Asellus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Myl\u00e9us","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Norstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"issue":"11","key":"3601_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075362","volume":"8","author":"DJ Smith","year":"2013","unstructured":"Smith DJ, Nicholl BI, Cullen B,\u2009 Martin D, Ul-Haq Z, Evans J, et al. Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. PLoS One. 2013;8(11):e75362.","journal-title":"PLoS One"},{"key":"3601_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jad.2017.06.043","volume":"221","author":"D Feifel","year":"2017","unstructured":"Feifel D, Malcolm B, Boggie D, Lee K. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. J Affect Disord. 2017;221:283\u20138.","journal-title":"J Affect Disord"},{"key":"3601_CR3","unstructured":"NICE. Depression in adults: recognition and management. 2020. https:\/\/www.nice.org.uk\/guidance\/cg90. Accessed 6 Apr 2019."},{"key":"3601_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k5354","volume":"363","author":"G McLachlan","year":"2018","unstructured":"McLachlan G. Treatment resistant depression: what are the options? Bmj. 2018;363:k5354.","journal-title":"Bmj."},{"key":"3601_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PPA.S29716","volume":"6","author":"KS Al-Harbi","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369\u201388.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3601_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1017\/S1121189X00003201","volume":"13","author":"SB Patten","year":"2004","unstructured":"Patten SB, Lee RC. Towards a dynamic description of major depression epidemiology. Epidemiol Psichiatr Soc. 2004;13(1):21\u20138.","journal-title":"Epidemiol Psichiatr Soc."},{"issue":"4","key":"3601_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/00019442-200504000-00002","volume":"13","author":"RM Greenberg","year":"2005","unstructured":"Greenberg RM, Kellner CH. Electroconvulsive therapy: a selected review. Am J Geriatr Psychiatry. 2005;13(4):268\u201381.","journal-title":"Am J Geriatr Psychiatry"},{"key":"3601_CR8","doi-asserted-by":"publisher","unstructured":"Rhee TG, Sint K, Olfson M, Gerhard T, S HB, Wilkinson ST. Association of ECT with risks of all-cause mortality and suicide in older Medicare patients. Am J Psychiatry. 2021. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21040351.","DOI":"10.1176\/appi.ajp.2021.21040351"},{"issue":"5","key":"3601_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1176\/appi.ps.201700364","volume":"69","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson ST, Agbese E, Leslie DL, Rosenheck RA. Identifying recipients of electroconvulsive therapy: data from privately insured Americans. Psychiatr Serv. 2018;69(5):542\u20138.","journal-title":"Psychiatr Serv"},{"issue":"4","key":"3601_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/YCT.0000000000000400","volume":"33","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson ST, Rosenheck RA. Electroconvulsive therapy at a veterans health administration medical center. J ect. 2017;33(4):249\u201352.","journal-title":"J ect."},{"issue":"4","key":"3601_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/YCT.0000000000000405","volume":"33","author":"U Rakita","year":"2017","unstructured":"Rakita U, Bingham K, Fung K, Giacobbe P. Factors associated with global variability in electroconvulsive therapy utilization. J ect. 2017;33(4):253\u20139.","journal-title":"J ect"},{"key":"3601_CR12","unstructured":"Royal College of Psychiatrists. ECT minimum dataset 2016\u201317 activity data report \u2013 England, Wales, Northern Ireland & Republic of Ireland. Royal College of Psychiatrists. 2017. https:\/\/www.rcpsych.ac.uk\/docs\/default-source\/improving-care\/ccqi\/quality-networks\/electro-convulsive-therapy-clinics-(ectas)\/ectas-dataset-report-2016-17.pdf. Accessed 20 Mar 2021."},{"key":"3601_CR13","unstructured":"NICE. Guidance on the use of electroconvulsive therapy. 2009. https:\/\/www.nice.org.uk\/guidance\/ta59. Accessed 6 Apr 2019."},{"key":"3601_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jad.2020.11.123","volume":"281","author":"JKE Veraart","year":"2021","unstructured":"Veraart JKE, Smith-Apeldoorn SY, Spaans HP, Kamphuis J, Schoevers RA. Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review. J Affect Disord. 2021;281:82\u20139.","journal-title":"J Affect Disord"},{"issue":"4","key":"3601_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11126-020-09830-6","volume":"91","author":"RI Memon","year":"2020","unstructured":"Memon RI, Naveed S, Faquih AE, Fida A, Abbas N, Chaudhary AMD, et al. Effectiveness and safety of ketamine for unipolar depression: a systematic review. Psychiatr Q. 2020;91(4):1147\u201392.","journal-title":"Psychiatr Q"},{"key":"3601_CR16","doi-asserted-by":"publisher","unstructured":"Mahase E. Esketamine is approved in Europe for treating resistant major depressive disorder. BMJ. 2019; https:\/\/doi.org\/10.1136\/bmj.l7069.","DOI":"10.1136\/bmj.l7069"},{"key":"3601_CR17","unstructured":"FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic. 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Accessed 10 Apr 2019."},{"key":"3601_CR18","volume-title":"Decision modelling for health economic evaluation","author":"B Andrew","year":"2006","unstructured":"Andrew B, Karl C, Mark S. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"issue":"1","key":"3601_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12913-020-5050-9","volume":"20","author":"A Gandjour","year":"2020","unstructured":"Gandjour A. Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG. BMC Health Serv Res. 2020;20(1):343.","journal-title":"BMC Health Serv Res"},{"key":"3601_CR20","doi-asserted-by":"publisher","unstructured":"Appleby J, Devlin N, Parkin D. NICE's cost effectiveness threshold. BMJ. 2007. https:\/\/doi.org\/10.1136\/bmj.39308.560069.BE.","DOI":"10.1136\/bmj.39308.560069.BE"},{"issue":"8","key":"3601_CR21","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1177\/0272989X16656165","volume":"36","author":"J Chhatwal","year":"2016","unstructured":"Chhatwal J, Jayasuriya S, Elbasha EH. Changing cycle lengths in state-transition models: challenges and solutions. Med Decis Mak. 2016;36(8):952\u201364.","journal-title":"Med Decis Mak"},{"issue":"7","key":"3601_CR22","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/S0033291714002554","volume":"45","author":"L Vallejo-Torres","year":"2015","unstructured":"Vallejo-Torres L, Castilla I, Gonz\u00e1lez N, Hunter R, Serrano-P\u00e9rez P, Perestelo-P\u00e9rez L. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model. Psychol Med. 2015;45(7):1459\u201370.","journal-title":"Psychol Med"},{"issue":"3","key":"3601_CR23","first-page":"164","volume":"65","author":"KP Fitzgibbon","year":"2020","unstructured":"Fitzgibbon KP, Plett D, Chan BCF, Hancock-Howard R, Coyte PC, Blumberger DM. Cost-utility analysis of electroconvulsive therapy and repetitive transcranial magnetic stimulation for treatment-resistant depression in Ontario. Can J Psychiatr. 2020;65(3):164\u201373.","journal-title":"Can J Psychiatr"},{"key":"3601_CR24","unstructured":"Janssen. Spravato. 2020. http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/SPRAVATO-pi.pdf. Accessed 04 Mar 2020."},{"issue":"6","key":"3601_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/09638237.2017.1417562","volume":"27","author":"P McCrone","year":"2018","unstructured":"McCrone P, Rost F, Koeser L, Koutoufa I, Stephanou S, Knapp M, et al. The economic cost of treatment-resistant depression in patients referred to a specialist service. J Ment Health. 2018;27(6):567\u201373.","journal-title":"J Ment Health"},{"issue":"9","key":"3601_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of Esketamine nasal spray plus Oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893\u2013903.","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"3601_CR27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","volume":"22","author":"M Fedgchin","year":"2019","unstructured":"Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose Esketamine nasal spray combined with a new Oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"3601_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1176\/ajp.2007.164.1.73","volume":"164","author":"S Eranti","year":"2007","unstructured":"Eranti S, Mogg A, Pluck G, Landau S, Purvis R, Brown RG, et al. A randomized, controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am J Psychiatry. 2007;164(1):73\u201381.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"3601_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/YCT.0b013e318276591f","volume":"29","author":"A Nordenskj\u00f6ld","year":"2013","unstructured":"Nordenskj\u00f6ld A, von Knorring L, Ljung T, Carlborg A, Brus O, Engstr\u00f6m I. Continuation electroconvulsive therapy with pharmacotherapy versus pharmacotherapy alone for prevention of relapse of depression: a randomized controlled trial. J ect. 2013;29(2):86\u201392.","journal-title":"J ect."},{"issue":"11","key":"3601_CR30","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"3601_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jad.2018.06.030","volume":"238","author":"J Reutfors","year":"2018","unstructured":"Reutfors J, Andersson TM, Brenner P, Brandt L, DiBernardo A, Li G, et al. Mortality in treatment-resistant unipolar depression: a register-based cohort study in Sweden. J Affect Disord. 2018;238:674\u20139.","journal-title":"J Affect Disord"},{"issue":"10","key":"3601_CR32","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1017\/S0033291718002210","volume":"49","author":"J Das-Munshi","year":"2019","unstructured":"Das-Munshi J, Chang CK, Schofield P, Stewart R, Prince MJ. Depression and cause-specific mortality in an ethnically diverse cohort from the UK: 8-year prospective study. Psychol Med. 2019;49(10):1639\u201351.","journal-title":"Psychol Med"},{"issue":"7","key":"3601_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1742-1241.2006.00997.x","volume":"60","author":"P Sobocki","year":"2006","unstructured":"Sobocki P, Ekman M, Agren H, Runeson B, Jonsson B. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract. 2006;60(7):791\u20138.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"3601_CR34","first-page":"726","volume":"24","author":"EJ Groessl","year":"2018","unstructured":"Groessl EJ, Tally SR, Hillery N, Maciel A, Garces JA. Cost-effectiveness of a Pharmacogenetic test to guide treatment for major depressive disorder. J Manag Care Spec Pharm. 2018;24(8):726\u201334.","journal-title":"J Manag Care Spec Pharm."},{"key":"3601_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/1472-6963-13-173","volume":"13","author":"N Maniadakis","year":"2013","unstructured":"Maniadakis N, Kourlaba G, Mougiakos T, Chatzimanolis I, Jonsson L. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece. BMC Health Serv Res. 2013;13:173.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"3601_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10198-009-0173-2","volume":"10","author":"JB Ten","year":"2009","unstructured":"Ten JB. Arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357\u20139.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"3601_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2307\/3349801","volume":"60","author":"TA Hodgson","year":"1982","unstructured":"Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60(3):429\u201362.","journal-title":"Milbank Mem Fund Q Health Soc"},{"issue":"20","key":"3601_CR38","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1001\/jama.1989.03430200123038","volume":"262","author":"JM Eisenberg","year":"1989","unstructured":"Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. Jama. 1989;262(20):2879\u201386.","journal-title":"Jama."},{"key":"3601_CR39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/CEOR.S44866","volume":"5","author":"BR Lensberg","year":"2013","unstructured":"Lensberg BR, Drummond MF, Danchenko N, Despiegel N, Francois C. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. Clinicoecon Outcomes Res. 2013;5:565\u201373.","journal-title":"Clinicoecon Outcomes Res"},{"key":"3601_CR40","unstructured":"ONS. Employee earnings in the UK: 2019. 2019. https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/bulletins\/annualsurveyofhoursandearnings\/2019. Accessed 06 Jun 2020."},{"key":"3601_CR41","unstructured":"NHS. National Cost Collection for the NHS. 2020. https:\/\/www.england.nhs.uk\/national-cost-collection\/. Accessed 10 Jun 2020."},{"key":"3601_CR42","unstructured":"Tfl. Pay as you go caps. 2020. https:\/\/tfl.gov.uk\/fares\/find-fares\/tube-and-rail-fares\/pay-as-you-go-caps. Accessed 06 Jun 2020."},{"issue":"4","key":"3601_CR43","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/ner.12723","volume":"21","author":"YJ Zhao","year":"2018","unstructured":"Zhao YJ, Tor PC, Khoo AL, Teng M, Lim BP, Mok YM. Cost-effectiveness modeling of repetitive transcranial magnetic stimulation compared to electroconvulsive therapy for treatment-resistant depression in Singapore. Neuromodulation. 2018;21(4):376\u201382.","journal-title":"Neuromodulation."},{"key":"3601_CR44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jad.2017.04.019","volume":"218","author":"AH Young","year":"2017","unstructured":"Young AH, Evitt L, Brignone M, Diamand F, Atsou K, Campbell R, et al. Cost-utility evaluation of vortioxetine in patients with major depressive disorder experiencing inadequate response to alternative antidepressants in the United Kingdom. J Affect Disord. 2017;218:291\u20138.","journal-title":"J Affect Disord"},{"issue":"8","key":"3601_CR45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40263-015-0267-6","volume":"29","author":"AL Khoo","year":"2015","unstructured":"Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, et al. Network Meta-analysis and cost-effectiveness analysis of new generation antidepressants. CNS Drugs. 2015;29(8):695\u2013712.","journal-title":"CNS Drugs"},{"issue":"5","key":"3601_CR46","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jval.2015.04.004","volume":"18","author":"KH Nguyen","year":"2015","unstructured":"Nguyen KH, Gordon LG. Cost-effectiveness of repetitive transcranial magnetic stimulation versus antidepressant therapy for treatment-resistant depression. Value Health. 2015;18(5):597\u2013604.","journal-title":"Value Health"},{"issue":"1","key":"3601_CR47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.schres.2003.10.010","volume":"71","author":"LA Lenert","year":"2004","unstructured":"Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004;71(1):155\u201365.","journal-title":"Schizophr Res"},{"issue":"1","key":"3601_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5498\/wjp.v9.i1.1","volume":"9","author":"G Gazdag","year":"2019","unstructured":"Gazdag G, Ungvari GS. Electroconvulsive therapy: 80 years old and still going strong. World J Psychiatry. 2019;9(1):1\u20136.","journal-title":"World J Psychiatry"},{"issue":"10","key":"3601_CR49","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1176\/appi.ps.201900625","volume":"71","author":"EL Ross","year":"2020","unstructured":"Ross EL, Soeteman DI. Cost-effectiveness of Esketamine nasal spray for patients with treatment-resistant depression in the United States. Psychiatr Serv. 2020;71(10):988\u201397.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"3601_CR50","first-page":"16","volume":"26","author":"F Agboola","year":"2020","unstructured":"Agboola F, Atlas SJ, Touchette DR, Fazioli K, Pearson SD. The effectiveness and value of Esketamine for the Management of Treatment-Resistant Depression. J Manag Care Spec Pharm. 2020;26(1):16\u201320.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"3601_CR51","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","volume":"6","author":"EH Turner","year":"2019","unstructured":"Turner EH. Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry. 2019;6(12):977\u20139.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"3601_CR52","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/ijnp\/pyaa027","volume":"23","author":"M Nijs","year":"2020","unstructured":"Nijs M, Wajs E, Aluisio L, Turkoz I, Daly E, Janik A, et al. Managing Esketamine treatment frequency toward successful outcomes: analysis of phase 3 data. Int J Neuropsychopharmacol. 2020;23(7):426\u201333.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"12","key":"3601_CR53","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1038\/npp.2013.149","volume":"38","author":"A Jelovac","year":"2013","unstructured":"Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: a meta-analysis. Neuropsychopharmacology. 2013;38(12):2467\u201374.","journal-title":"Neuropsychopharmacology."},{"issue":"4","key":"3601_CR54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1017\/S1121189X00002451","volume":"16","author":"M Knapp","year":"2007","unstructured":"Knapp M, Mangalore R. The trouble with QALYs. Epidemiol Psichiatr Soc. 2007;16(4):289\u201393.","journal-title":"Epidemiol Psichiatr Soc"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-021-03601-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T01:03:05Z","timestamp":1666832585000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03601-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3601"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03601-8","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"assertion":[{"value":"27 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PA has received consulting fees from Janssen. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"610"}}